Extavia (interferon beta-1b) is indicated for the treatment of:
- Patients with a single demyelinating event with an active inflammatory process severe enough to require iv corticosteroids if alternative diagnoses have been excluded and they are at high risk of developing multiple sclerosis.
- Relapsing-remitting multiple sclerosis in patients who have had at least two relapses in the preceding two years.
- Secondary progressive multiple sclerosis with active disease evidenced by relapses.
Interferons are an established treatment option for multiple sclerosis. The exact mechanism of action is unknown although they are throught to work through immunomodulatory effects.
Further information: Novartis
